• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    UBS initiated coverage on RLX Technology with a new price target

    8/8/23 9:12:45 AM ET
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $RLX alert in real time by email
    UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60
    Get the next $RLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RLX

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    More analyst ratings

    $RLX
    SEC Filings

    See more
    • SEC Form 20-F filed by RLX Technology Inc.

      20-F - RLX Technology Inc. (0001828365) (Filer)

      4/17/25 4:01:47 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      3/14/25 6:10:16 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      11/15/24 4:01:25 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Financials

    Live finance-specific insights

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 14, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on March 14, 2025 - SHENZHEN, China, March 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before the U.S. markets open on Friday, March 14, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 14, 2025 (8:00 PM Beijing/Hong Kong Time on March 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412

      3/3/25 10:30:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Files 2024 Annual Report on Form 20-F

      SHENZHEN, China, April 17, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC") on April 17, 2025. The annual report on Form 20-F can be accessed on the SEC's website at https://www.sec.gov and on the Company's investor relations website at https://ir.relxtech.com. The Company will provide a hard copy of its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. About RLX Technology Inc. RLX Techno

      4/17/25 8:00:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/7/24 6:06:29 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/6/24 4:01:28 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/14/23 6:01:42 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    $RLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RLX Technology downgraded by Citigroup with a new price target

      Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

      3/17/25 7:42:34 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • UBS initiated coverage on RLX Technology with a new price target

      UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

      8/8/23 9:12:45 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care